Oksana Koneva

Castle Biosciences unveils findings from three Barrett Esophagus studies at ACG 2026

Castle Biosciences unveils findings from three Barrett Esophagus studies at ACG 2026
Castle Biosciences set for ACG 2026

Castle Biosciences announced it will present new data from three studies evaluating its TissueCypher Barrett Esophagus test at the American College of Gastroenterology 2026 Annual Scientific Meeting and Postgraduate Course. The event is scheduled for October 9-14 in Nashville, Tennessee.

The presented studies are expected to offer fresh insights into the clinical value of the TissueCypher test for Barrett Esophagus patients. Castle Biosciences did not disclose further details about the study results in the announcement.

A previous Castle Biosciences study found that the TissueCypher Barrett Esophagus Test changed management plans in 90 percent of NDBE cases, according to company data. The firm also expanded its operational footprint with the opening of a new laboratory and office facility in Scottsdale, Arizona, as detailed in a separate announcement.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.